![]() | |
Clinical data | |
---|---|
Other names | LY3484356 |
Legal status | |
Legal status |
|
Identifiers | |
| |
PubChem CID | |
ChemSpider | |
UNII | |
ChEMBL | |
Chemical and physical data | |
Formula | C29H24F4N2O3 |
Molar mass | 524.516 g·mol−1 |
3D model (JSmol) | |
| |
|
Imlunestrant is an experimental selective estrogen receptor degrader developed by Eli Lilly and Company for the treatment of some types of breast cancer.[1][2][3]